NOTICE

The week at the BIO conference in Boston was highly successful for Onegene Biotechnology. Undeniably, the conference served as an unparalleled platform to engage in direct discussions with representatives from pharmaceutical/biotech firms, investors, service providers, and key industry stakeholders. It was extremely productive, offering us the opportunity to rekindle relationships with old acquaintances, share ideas, and gain insights. As we gear up for our first-in-human clinical trial of our leading pipeline(OGB21502) for NASH, it was truly fruitful meetings where we were able to amass a wealth of insights from perspectives of global professionals, contributing immensely to our growth and understanding.